Skip to main content

Table 1 Experimental design of mouse vaccination and challenge

From: Potential of recombinant inorganic pyrophosphatase antigen as a new vaccine candidate against Baylisascaris schroederi in mice

Trial and experimental group Number of mice 0, 2, 4 wpv b 6-wpv b 1-wpc c 1-11 wpc c(80-dpc)
   Vaccination Cytokine assay Challenge Larval recovery Mortality
(Trial I)   (3 times per group) (No. a) (No. a, d) (No. a) (No. a)
rBsc-PYP-1/FCA/PBS 30 rBsc-PYP-1 (FCA plus PBS) 10 20 10 10
FCA/PBS 30 FCA plus PBS 10 20 10 10
PBS 30 PBS 10 20 10 10
Trial and experimental group Number of mice 0, 2, 4 wpv b 5-wpv b 6-wpv b 1-wpc c 1-12 wpc c (80-dpc)
   Vaccination Challenge Cytokine assay Larval recovery Mortality
(Trial II)   (3 times per group) (No. a ) (No. a, e ) (No. a, f ) (No. a )
rBsc-PYP-1/FCA/PBS 30 rBsc-PYP-1 (FCA plus PBS) 20 10 10 -
FCA/PBS 30 FCA plus PBS 20 10 10 -
PBS 30 PBS 20 10 10 -
  1. a Number of mice involved in this assay.
  2. b Week(s) post-vaccination.
  3. c Week(s) post-challenge.
  4. d Number of remaining mice in each experimental group after “Cytokine assay” and used for the subsequent determinations of “Larval recovery” and “Mortality”.
  5. e Number of remaining mice in each experimental group after “Challenge”.
  6. f Number of mice derived from “Challenge”.